poSt Covid-19 Infection centraL Sensitisation 2 (SILENT 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04701892|
Recruitment Status : Unknown
Verified January 2021 by Universitair Ziekenhuis Brussel.
Recruitment status was: Recruiting
First Posted : January 8, 2021
Last Update Posted : January 22, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Covid19||Other: Indicators of central sensitisation|
The COVID-19 pandemic is currently a serious global public health concern. This disease is caused by a novel coronavirus which was first discovered in Wuhan, China in 2019 and later spread rapidly throughout the world. Symptoms of the disease can manifest as fever, cough, encephalitis, myalgia, fatigue, muscle weakness, arthralgia, anosmia, and impairment in other bodily functions in the acute phase. In 17% to 67% of cases, COVID-19 patients will develop acute respiratory distress syndrome (ARDS) and critical illness. Besides the impact on the respiratory system, coronaviruses have an effect on other systems including the central nervous system, cardiovascular system, musculoskeletal system, and gastrointestinal system.
The term central sensitivity syndrome (CSS) describes a group of medically nonspecific disorders, such as fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome, for which central sensitivity might be a common etiology. Despite the lack of a solid outcome measurement, the Central Sensitization Inventory (CSI) was previously introduced as a screening instrument for clinicians to help identify patients with a CSS. Furthermore, quantitative sensory testing can be used to identify and quantify sensory disfunctions by evaluating a variety of parameters including pain thresholds, temporal summation, and conditioned pain modulation (CPM). Previous research in patients with chronic pain resulted in less efficacious CPM, increased nociceptive facilitation and decreased pain thresholds.
In post covid-19 patients, potential long-term secondary effects on the musculoskeletal system such as muscle weakness, decreased muscle mass, and myopathies have been brought under attention. Persisting symptoms are a frequently reported complaint in patients recovered from COVID-19 infection with at least 1 symptom, particularly fatigue and dyspnea. Fatigue is also one of the core symptoms in central sensitisation disorders, leading to the hypothesis that central sensitisation might be the underlying common etiology in chronic pain patients and patients post COVID-19 infection. Therefore, the aim of this study is to evaluate whether there are indicators of central sensitisation in patients post covid-19 infection.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Central Sensitisation in Post Covid-19 Infection Patients: a Prospective Cohort Study|
|Actual Study Start Date :||January 19, 2021|
|Estimated Primary Completion Date :||January 2023|
|Estimated Study Completion Date :||January 2023|
Covid-19 infected patients
In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
Other: Indicators of central sensitisation
Indicators of central sensitisation, assessed by the Central Sensitization Inventory
- Symptoms of Central Sensitisation [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Symptoms of central sensitisation will be measured with the Central Sensitization Inventory.
- Pressure pain thresholds [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Pressure pain thresholds will be measured at the trapezius and rectus femoris muscles with an algometer.
- Temporal summation [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Temporal summation will be measured with 10 consecutive pressure pulses at the trapezius and rectus femoris muscles with an algometer.
- Descending nociceptive inhibition [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Descending nociceptive inhibition will be measured with a conditioned pain modulation protocol with algometer as test stimulus and the cold pressor task.
- Functionality and disability [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Functional status will be evaluated by the Post-COVID-19 Functional Status Scale.
- Functionality and disability [ Time Frame: The change between baseline, 3 months, 6 months (primary time endpoint) and 12 months ]Level of dyspnea during activities of daily living will be evaluated by the London chest Activity of Daily Living scale.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Sampling Method:||Non-Probability Sample|
- Patients with a diagnosed covid-19 infection that took place 2-8 weeks before study inclusion.
- Cognitive and language functioning enabling coherent communication between the researcher and the participant.
- French-or Dutch speaking persons.
- Covid-19 infection > 8 weeks ago.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04701892
|Contact: Marc Schiltz, MD||+32 2 477 60 email@example.com|
|Universitair Ziekenhuis Brussel||Recruiting|
|Jette, Brussel, Belgium, 1090|
|Contact: Marc Schiltz, MD +32 2 477 60 20 firstname.lastname@example.org|
|Principal Investigator: Marc Schiltz|
|Sub-Investigator: Ann De Smedt|
|Sub-Investigator: Samar Hatem|
|Sub-Investigator: Maarten Moens|
|Sub-Investigator: Lisa Goudman|
|Responsible Party:||Universitair Ziekenhuis Brussel|
|Other Study ID Numbers:||
|First Posted:||January 8, 2021 Key Record Dates|
|Last Update Posted:||January 22, 2021|
|Last Verified:||January 2021|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases